文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

静脉给予白细胞介素-7逆转脓毒症休克患者淋巴细胞减少:双盲、随机、安慰剂对照试验

Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial.
PubMed 文献 · Ann Intensive Care · 2023-03-12
一句话结论静脉CYT107可逆转脓毒症诱导的淋巴细胞减少,但3/15例出现发热和呼吸窘迫,作者认为肌内给药更可取。

这项前瞻性、双盲、安慰剂对照试验拟纳入40例脓毒症患者,按3:1随机接受静脉CYT107(10 µg/kg)或安慰剂,随访至90天。实际在法国8个和美国2个中心纳入21例(CYT107组15例、安慰剂组6例),因CYT107组3/15例在给药后约5-8小时出现发热和呼吸窘迫而提前终止。静脉CYT107使绝对淋巴细胞计数(包括CD4+和CD8+ T细胞,均p<0.05)较安慰剂增加2-3倍,与肌内给药相似,并逆转严重淋巴细胞减少、与器官支持无衰竭天数增加相关;但静脉CYT107血药浓度较肌内CYT107升高约100倍,未观察到细胞因子风暴和抗CYT107抗体形成。作者认为,基于实验室和临床反应相当、药代动力学更有利和耐受性更好,肌内给予CYT107更可取。

要点

  • 静脉CYT107(10 µg/kg)使绝对淋巴细胞计数较安慰剂增加2-3倍(CD4+和CD8+ T细胞均p<0.05),并逆转严重淋巴细胞减少。
  • CYT107组15例中3例在给药后约5-8小时出现发热和呼吸窘迫,试验因此提前终止;无长期后遗症。
  • 静脉CYT107血药浓度较肌内CYT107升高约100倍,但未观察到细胞因子风暴和抗CYT107抗体形成。
  • 静脉CYT107与器官支持无衰竭天数(OSFD)增加相关,实验室和临床反应与肌内给药相似。
  • 作者认为,因药代动力学更有利、耐受性更好,肌内给予CYT107更可取。

适用人群与场景

  • 脓毒症患者(原文为sepsis patients),拟纳入40例,实际纳入21例;来自法国8个和美国2个中心。

处置流程与药物剂量

  • CYT107(糖基化重组人IL-7)10 µg/kg静脉给药,随机3:1分配至CYT107或安慰剂,随访至90天。

红旗征与不能漏的情况

  • 静脉CYT107给药后约5-8小时出现发热和呼吸窘迫(CYT107组15例中3例),试验因此提前终止;原文未报告长期后遗症。

研究设计与关键结果

  • 前瞻性、双盲、安慰剂对照试验,拟纳入40例脓毒症患者,实际纳入21例(CYT107组15例、安慰剂组6例),来自法国8个和美国2个中心。
  • 因CYT107组15例中3例在给药后约5-8小时出现发热和呼吸窘迫,试验提前终止。
  • 静脉CYT107使绝对淋巴细胞计数较安慰剂增加2-3倍(包括CD4+和CD8+ T细胞,均p<0.05),该增加与肌内给予CYT107相似,并在整个随访期间维持,逆转了严重淋巴细胞减少,且与器官支持无衰竭天数(OSFD)增加相关。
  • 静脉CYT107血药浓度较肌内CYT107升高约100倍。
  • 未观察到细胞因子风暴和抗CYT107抗体形成。

证据类型、等级与局限

  • 证据类型:前瞻性、双盲、随机、安慰剂对照试验(II期)。
  • 局限:原文报告因CYT107组3/15例出现发热和呼吸窘迫而提前终止,实际纳入21例(拟纳入40例)。

对床旁实践的改变

  • 作者认为,基于实验室和临床反应相当、药代动力学更有利和患者耐受性更好,肌内给予CYT107比静脉给药更可取。

指南或共识出处

  • Clinicaltrials.gov注册号NCT03821038,注册日期2019年1月29日。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Profound lymphopenia is an independent predictor of adverse clinical outcomes in sepsis. Interleukin-7 (IL-7) is essential for lymphocyte proliferation and survival. A previous phase II study showed that CYT107, a glycosylated recombinant human IL-7, administered intramuscularly reversed sepsis-induced lymphopenia and improved lymphocyte function. Thepresent study evaluated intravenous administration of CYT107. This prospective, double-blinded, placebo-controlled trial was designed to enroll 40 sepsis patients, randomized 3:1 to CYT107 (10 µg/kg) or placebo, for up to 90 days.

RESULTS: Twenty-one patients were enrolled (fifteen CYT107 group, six placebo group) at eight French and two US sites. The study was halted early because three of fifteen patients receiving intravenous CYT107 developed fever and respiratory distress approximately 5-8 h after drug administration. Intravenous administration of CYT107 resulted in a two-threefold increase in absolute lymphocyte counts (including in both CD4+ and CD8+ T cells (all p < 0.05)) compared to placebo. This increase was similar to that seen with intramuscular administration of CYT107, was maintained throughout follow-up, reversed severe lymphopenia and was associated with increase in organ support free days (OSFD). However, intravenous CYT107 produced an approximately 100-fold increase in CYT107 blood concentration compared with intramuscular CYT107. No cytokine storm and no formation of antibodies to CYT107 were observed.

CONCLUSION: Intravenous CYT107 reversed sepsis-induced lymphopenia. However, compared to intramuscular CYT107 administration, it was associated with transient respiratory distress without long-term sequelae. Because of equivalent positive laboratory and clinical responses, more favorable pharmacokinetics, and better patient tolerability, intramuscular administration of CYT107 is preferable.

TRIAL REGISTRATION: Clinicaltrials.gov, NCT03821038. Registered 29 January 2019, https://clinicaltrials.gov/ct2/show/NCT03821038?term=NCT03821038&draw=2&rank=1 .

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Daix T, Mathonnet A, Brakenridge S, et al. Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial. Ann Intensive Care. 2023. PMID: 36906875. doi:10.1186/s13613-023-01109-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。